ANGLE plc (AGL) - Total Liabilities
Based on the latest financial reports, ANGLE plc (AGL) has total liabilities worth GBX6.39 Million GBX (≈ $777.48 USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore cash efficiency ratio of ANGLE plc to assess how effectively this company generates cash.
ANGLE plc - Total Liabilities Trend (2001–2024)
This chart illustrates how ANGLE plc's total liabilities have evolved over time, based on quarterly financial data. Check AGL asset liquidity ratio to evaluate the company's liquid asset resilience ratio.
ANGLE plc Competitors by Total Liabilities
The table below lists competitors of ANGLE plc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Renalytix AI plc
LSE:RENX
|
UK | GBX12.81 Million |
|
G2Power Co. Ltd.
KQ:388050
|
Korea | ₩50.51 Billion |
|
Fiske PLC
LSE:FKE
|
UK | GBX4.34 Million |
|
QVC Group Inc.
NASDAQ:QVCGB
|
USA | $10.54 Billion |
|
Kendrick Resources PLC
LSE:KEN
|
UK | GBX1.09 Million |
|
Montage Gold Corp.
TO:MAU
|
Canada | CA$432.22 Million |
Liability Composition Analysis (2001–2024)
This chart breaks down ANGLE plc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see AGL market cap.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.13 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.55 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.35 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how ANGLE plc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for ANGLE plc (2001–2024)
The table below shows the annual total liabilities of ANGLE plc from 2001 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | GBX7.02 Million ≈ $853.77 |
-14.88% |
| 2023-12-31 | GBX8.24 Million ≈ $1.00K |
-15.92% |
| 2022-12-31 | GBX9.80 Million ≈ $1.19K |
+40.37% |
| 2021-12-31 | GBX6.99 Million ≈ $849.87 |
+48.46% |
| 2020-12-31 | GBX4.71 Million ≈ $572.46 |
+18.28% |
| 2019-12-31 | GBX3.98 Million ≈ $484.01 |
+7.98% |
| 2019-04-30 | GBX3.68 Million ≈ $448.24 |
+53.63% |
| 2018-04-30 | GBX2.40 Million ≈ $291.77 |
+13.54% |
| 2017-04-30 | GBX2.11 Million ≈ $256.97 |
+40.43% |
| 2016-04-30 | GBX1.50 Million ≈ $182.99 |
+32.98% |
| 2015-04-30 | GBX1.13 Million ≈ $137.61 |
+75.35% |
| 2014-04-30 | GBX645.00K ≈ $78.48 |
-12.41% |
| 2013-04-30 | GBX736.42K ≈ $89.60 |
-5.47% |
| 2012-04-30 | GBX779.00K ≈ $94.78 |
+8.04% |
| 2011-04-30 | GBX721.00K ≈ $87.72 |
-42.18% |
| 2010-04-30 | GBX1.25 Million ≈ $151.72 |
-23.45% |
| 2009-04-30 | GBX1.63 Million ≈ $198.20 |
-16.85% |
| 2008-04-30 | GBX1.96 Million ≈ $238.35 |
-4.21% |
| 2007-04-30 | GBX2.04 Million ≈ $248.82 |
+24.77% |
| 2006-04-30 | GBX1.64 Million ≈ $199.42 |
0.00% |
| 2005-04-30 | GBX1.64 Million ≈ $199.42 |
+53.18% |
| 2004-04-30 | GBX1.07 Million ≈ $130.19 |
+112.72% |
| 2003-04-30 | GBX503.00K ≈ $61.20 |
+32.72% |
| 2002-04-30 | GBX379.00K ≈ $46.11 |
+6.16% |
| 2001-04-30 | GBX357.00K ≈ $43.44 |
-- |
About ANGLE plc
ANGLE plc, a medical diagnostic company, develops cancer diagnostics products in the United Kingdom, Europe, North America, and internationally. The company develops Parsortix PC1 systems, a medical device for the capture and harvest of intact circulating tumour cells (CTCs) from metastatic breast cancer patient blood for subsequent user-validated downstream analysis. It also provides Portrait+ C… Read more